Evaxion (EVAX) Aktievy
Evaxion A/S, ett bioteknikbolag i klinisk fas, utvecklar immunologiska vacciner som drivs av artificiell intelligens. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
EVAX Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Evaxion A/S Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$3.21 |
| 52 veckors högsta | US$12.15 |
| 52 veckors lägsta | US$2.52 |
| Beta | 0.25 |
| 1 månads förändring | 5.97% |
| 3 månaders förändring | -18.09% |
| 1 års förändring | 12.27% |
| 3 års förändring | -93.58% |
| 5 års förändring | -98.82% |
| Förändring sedan börsintroduktionen | -99.35% |
Senaste nyheter och uppdateringar
EVAX: Future Cancer Vaccine Data Will Drive Bullish Repricing Potential
Analysts have adjusted their price target on Evaxion from $19.75 to $16.00, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What’s in the News for Evaxion Evaxion plans to present new preclinical data for its cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop 2026 in Montreal, with the findings intended to guide final antigen selection for a broadly protective CMV vaccine candidate (source: recent news report).
EVAX: AI-Immunology Pipeline Progress Will Drive Future Upside Potential
Analysts have lowered their price target on Evaxion from $14.19 to $11.25, reflecting the application of a slightly higher discount rate and more moderate assumptions for revenue growth and profit margin, which in turn leads to a higher expected future P/E. What’s in the News for Evaxion Evaxion reported new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine candidate for acute myeloid leukemia, with poster data set for presentation at the European Hematology Association 2026 Congress in Stockholm, Sweden.Recent updates
EVAX: Future Cancer Vaccine Data Will Drive Bullish Repricing Potential
Analysts have adjusted their price target on Evaxion from $19.75 to $16.00, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What’s in the News for Evaxion Evaxion plans to present new preclinical data for its cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop 2026 in Montreal, with the findings intended to guide final antigen selection for a broadly protective CMV vaccine candidate (source: recent news report).EVAX: AI-Immunology Pipeline Progress Will Drive Future Upside Potential
Analysts have lowered their price target on Evaxion from $14.19 to $11.25, reflecting the application of a slightly higher discount rate and more moderate assumptions for revenue growth and profit margin, which in turn leads to a higher expected future P/E. What’s in the News for Evaxion Evaxion reported new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine candidate for acute myeloid leukemia, with poster data set for presentation at the European Hematology Association 2026 Congress in Stockholm, Sweden.
AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience
Catalysts About Evaxion Evaxion is a biotech company that applies its AI-Immunology platform to discover and design vaccines and immunotherapies in oncology, infectious disease and potentially autoimmune conditions. What are the underlying business or industry changes driving this perspective?Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025
Summary Evaxion has demonstrated impressive in-house capabilities for discovering and developing vaccine candidates for both infectious diseases and oncology indications. Partnership with MSD, albeit heavily backloaded, provides considerable validation of Evaxion's value. A potential option exercise by MSD expected later this year would bring in up to $10M. EVAX guides a cash runway into mid-2026, which could be extended into 2027 if MSD exercises options for both partnered candidates (not accounting for potential further business developments). EVAX aims for at least 2 new deals in 2025 and is in the meantime further developing its AI platform to stay ahead of competition. Read the full article on Seeking AlphaEvaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration
Summary Evaxion's sophisticated AI Immunology platform aims to outperform competitors in vaccine development, in both oncology and infectious diseases indications. The company has already established three collaborations, including a partnership with MSD, and has raised enough funding to last through 2024. Evaxion's AI models, including EDEN, RAVEN, PIONEER, ObsERV, and AI-DEEP, show promise in identifying protective antigens, designing effective and safe personalized cancer vaccines and predicting which patients will respond. Big pharma interest, pending catalysts in 2024, impressive proof-of-concept preclinical and clinical data are compelling enough for me for a small speculative position. However, the risk of considerably more dilutive funding as well as the very early stage of the pipeline make me give a "Hold" recommendation. Read the full article on Seeking AlphaEvaxion Biotech names Per Norlén as CEO
Evaxion Biotech (EVAX) said Wednesday Per Norlén joined the firm as CEO on Monday. Norlén is a physician and associate professor with over 20 years in the biotech sector, of which the last decade has been in executive leadership roles.Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer
Evaxion Biotech (EVAX) said it enrolled its first patient in a global phase 2b trial of its immunotherapy EVX-01 to treat melanoma, a type of skin cancer. The trial is being conducted at sites in the the U.S., Europe, and Australia in collaboration with Merck (NYSE:MRK) which is supplying the trial with its blockbuster drug Keytruda, the Danish company said in a Sept. 21 press release. Patients will receive standard of care treatment along with Keytruda in combination with EVX-01. Evaxion added that it is responsible for conducting the trial. The company expects interim topline data in H2 2023. EVAX +11.27% to $2.27 premarket Sept. 21Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10
Evaxion Biotech ADS press release (EVAX): Q2 GAAP EPS of -$0.20 beats by $0.10. As of June 30, 2022, cash and cash equivalents were $25.3M as compared to $32.2M as of December 31, 2021. We expect our existing cash and cash equivalents, including use of financing facilities, will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months.Evaxion Biotech announces new CEO as Lars Wegner resigns
Evaxion Biotech (EVAX) announced Tuesday the resignation of chief executive officer Lars Staal Wegner. The clinical-stage biotech company said Per Norlén, M.D., PhD., has been appointed to succeed Wegner. Norlén is a physician and board certified specialist in clinical pharmacology with over 20 years of working in clinical drug development. Most recently, Dr. Norlén was Chief Executive Officer of Targinta AB and Chief Medical Officer of Xintela AB, Targinta is a wholly owned subsidiary of Xintela, a publicly listed company on the Nasdaq First North Growth Market Stockholm, Sweden. Earlier: Evaxion Biotech to advance DNA vaccine into non-small cell lung cancer indicationAktieägarnas avkastning
| EVAX | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | 7.2% | 2.5% | 1.7% |
| 1Y | 12.3% | 37.4% | 20.0% |
Avkastning vs industri: EVAX presterade sämre än US Biotechs branschen som gav 37.4 % under det senaste året.
Avkastning vs Marknaden: EVAX presterade sämre än US marknaden som gav 20 % under det senaste året.
Prisvolatilitet
| EVAX volatility | |
|---|---|
| EVAX Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: EVAX har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: EVAX s veckovolatilitet har minskat från 16% till 8% under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2008 | 46 | Helen Tayton-Martin | evaxion.ai |
Evaxion A/S, ett bioteknikbolag i klinisk fas, utvecklar immunologiska vacciner som drivs av artificiell intelligens. Bolaget utvecklar EVX-01, som befinner sig i fas 2 i en global multicenterstudie för behandling av avancerat melanom; EVX-03, ett DNA-baserat cancervaccin för behandling av solida tumörer; och EVX-04, en terapeutisk cancervaccinkandidat, som befinner sig i fas 1 för behandling av akut myeloisk leukemi. Bolagets program omfattar även vacciner i preklinisk fas, däribland EVX-B1, ett multikomponent profylaktiskt vaccin mot hud- och mjukdelsinfektioner med S. aureus-bakterier; EVX-B2, ett multikomponent profylaktiskt vaccin mot gonorrébakterier; EVX-B3, ett profylaktiskt vaccin mot bakteriella patogener som är associerade med upprepade infektioner; och EVX-V1, en multikomponent profylaktisk vaccinkandidat mot cytomegalovirus.
Evaxion A/S Sammanfattning av grunderna
| EVAX grundläggande statistik | |
|---|---|
| Börsvärde | US$25.60m |
| Vinst(TTM) | -US$9.76m |
| Intäkter(TTM) | US$7.53m |
Är EVAX övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| EVAX resultaträkning (TTM) | |
|---|---|
| Intäkter | US$7.53m |
| Kostnad för intäkter | US$0 |
| Bruttovinst | US$7.53m |
| Övriga kostnader | US$17.28m |
| Intäkter | -US$9.76m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
Aug 20, 2026
| Vinst per aktie (EPS) | -1.17 |
| Bruttomarginal | 100.00% |
| Nettovinstmarginal | -129.60% |
| Skuld/egenkapitalförhållande | 0% |
Hur har EVAX utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/13 17:10 |
| Aktiekurs vid dagens slut | 2026/08/13 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Evaxion A/S bevakas av 6 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Soumit Roy | JonesTrading Institutional Services, LLC |
| Debanjana Chatterjee | JonesTrading Institutional Services, LLC |